Beratung zur HPV-Impfung bei jungen sexuell aktiven Frauen

Abstract

Der tetravalente Impfstoff gegen HPV 6, 11, 16, 18 (Gardasil ®) zur Prävention hochgradiger Zervixund Vulvadysplasien sowie zum Schutz vor Genitalwarzen ist seit über einem Jahr zugelassen. Ganz aktuell erhielt im September 2007 der bivalente Impfstoff gegen HPV 16, 18 (Cervarix ®) die Zulassung zur Prävention von hochgradigen, intraepithelialen Neoplasien des Gebärmutterhalses und Gebärmutterhalskrebs. Bei dem HPV

Anogenital Warts in Childhood – Always a Marker for Sexual Abuse?

“…After several decades of rapidly rising subclinical and clinical HPV infections, it is hoped that, following the introduction of the quadrivalent HPV-6,11,16,18 vaccine in October 2006, there will be a reduction in the number of cases in the coming decades and that the recommendation still given by the Center for Disease Control (CDC) in 2010 [58] that only refraining from sexual contact can prevent HPV infection will lose its relevance. In Australia, 12 months after the introduction of the vaccination programme, with a vaccination rate of 65-70 % in women under 28 [63], confirmed in August 2009 [64], that girls aged 12 to 17 should be vaccinated before their first sexual intercourse to prevent HPV-associated neoplasias, a vaccination rate of approximately 30 % has been achieved to date [65,66]. This rate needs to be increased, but in the collective vaccinated with the quadrivalent HPV-6,11,16,18 vaccine we are certain to see a reduction in the rate of new condylomata infections in the near future [67,68].…”